$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000101749118000059 Filed on May 03, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.080M	$2.140M	$1.440M
YoY Change	30.0%	48.61%	-35.14%
% of Gross Profit
Research & Development	$162.0K	$217.0K	$412.0K
YoY Change	-80.69%	-47.33%	-84.17%
% of Gross Profit
Depreciation & Amortization		$13.00K	$56.00K
YoY Change		-76.79%	-22.22%
% of Gross Profit
Operating Expenses	$2.237M	$2.352M	$1.853M
YoY Change	-8.36%	26.93%	-61.6%
Operating Profit	-$2.237M	-$2.352M	-$1.853M
YoY Change	-8.36%	26.93%	-61.6%
Interest Expense	$0.00	$0.00	-$95.00K
YoY Change	-100.0%	-100.0%	-65.95%
% of Operating Profit
Other Income/Expense, Net	-$16.00K	$81.00K	-$1.551M
YoY Change	-102.23%	-105.22%	-167.08%
Pretax Income	-$2.250M	-$2.270M	-$3.400M
YoY Change	30.81%	-33.24%	35.46%
Income Tax
% Of Pretax Income
Net Earnings	-$2.277M	-$2.271M	$8.073M
YoY Change	54.48%	-128.13%	-422.28%
Net Earnings / Revenue
Basic Earnings Per Share			$1.04
Diluted Earnings Per Share	-$2.923M	-$4.283M	$1.04
COMMON SHARES
Basic Shares Outstanding	23.44M shares	16.34M shares	7.737M shares
Diluted Shares Outstanding			7.737M shares

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.840M	$5.680M	$3.760M
YoY Change	-12.53%	51.06%	-45.59%
Cash & Equivalents	$6.836M	$5.678M	$3.762M
Short-Term Investments
Other Short-Term Assets	$290.0K	$240.0K	$1.380M
YoY Change	-65.06%	-82.61%	23.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$7.130M	$5.918M	$5.146M
YoY Change	-17.56%	15.0%	-43.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.00K	$66.00K	$142.0K
YoY Change	-53.72%	-53.52%	-88.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$36.00K	$65.00K
YoY Change	-20.0%	-44.62%	-16.67%
Total Long-Term Assets	$92.00K	$102.0K	$207.0K
YoY Change	-44.58%	-50.72%	-84.23%
TOTAL ASSETS
Total Short-Term Assets	$7.130M	$5.918M	$5.146M
Total Long-Term Assets	$92.00K	$102.0K	$207.0K
Total Assets	$7.222M	$6.020M	$5.353M
YoY Change	-18.07%	12.46%	-48.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.050M	$340.0K	$490.0K
YoY Change	650.0%	-30.61%	-55.45%
Accrued Expenses	$454.0K	$929.0K	$545.0K
YoY Change	-36.59%	70.46%	-81.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.903M	$1.690M	$2.590M
YoY Change	3.2%	-34.75%	-80.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$35.00K	$42.00K	$67.00K
YoY Change	-41.67%	-37.31%	-62.57%
Total Long-Term Liabilities	$35.00K	$42.00K	$67.00K
YoY Change	-41.67%	-37.31%	-62.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.903M	$1.690M	$2.590M
Total Long-Term Liabilities	$35.00K	$42.00K	$67.00K
Total Liabilities	$1.938M	$1.732M	$4.511M
YoY Change	-13.6%	-61.6%	-73.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$320.5M	-$318.3M	-$308.2M
YoY Change	3.5%	3.25%	-1.01%
Common Stock	$325.8M	$322.5M	$309.1M
YoY Change	3.02%	4.36%	1.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.284M	$4.288M	$842.0K
YoY Change
Total Liabilities & Shareholders Equity	$7.222M	$6.020M	$5.353M
YoY Change	-18.07%	12.46%	-48.69%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$2.277M	-$2.271M	$8.073M
YoY Change	54.48%	-128.13%	-422.28%
Depreciation, Depletion And Amortization		$13.00K	$56.00K
YoY Change		-76.79%	-22.22%
Cash From Operating Activities	-$330.0K	-$310.0K	-$2.700M
YoY Change	-85.46%	-88.52%	-55.9%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities			$11.50M
YoY Change			11400.0%
Cash From Investing Activities			$11.50M
YoY Change			-191766.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K	70.00K	-7.130M
YoY Change	-91.78%	-100.98%	-177.94%
NET CHANGE
Cash From Operating Activities	-330.0K	-310.0K	-2.700M
Cash From Investing Activities			11.50M
Cash From Financing Activities	500.0K	70.00K	-7.130M
Net Change In Cash	170.0K	-240.0K	1.670M
YoY Change	-95.81%	-114.37%	-44.7%
FREE CASH FLOW
Cash From Operating Activities	-$330.0K	-$310.0K	-$2.700M
Capital Expenditures			$0.00
Free Cash Flow			-$2.700M
YoY Change			-55.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2018Q1	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
CY2017Q1	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
CY2018Q1	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
CY2017Q1	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	0	USD
CY2018Q1	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	472000	USD
CY2017Q1	apri	Noncashor Part Noncash Transaction Costs Financing Activities NoncashorPartNoncashTransactionCostsFinancingActivities	0	USD
CY2018Q1	apri	Noncashor Part Noncash Transaction Costs Financing Activities NoncashorPartNoncashTransactionCostsFinancingActivities	135000	USD
CY2016Q1	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	709000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2018Q1	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2017Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	61000	USD
CY2018Q1	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	30000	USD
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0000
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	3837000	shares
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	4.22
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	1.48
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.73
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.00
CY2018Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	1.55
CY2018Q1	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	96500000	USD
CY2018Q1	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	472000	USD
CY2018Q1	apri	Working Capital WorkingCapital	4200000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23441080	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2018Q1	dei	Trading Symbol TradingSymbol	APRI
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58000	USD
CY2018Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	344000	USD
CY2017Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
CY2018Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	0	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	863000	USD
CY2018Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	417000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	929000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	575000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	853000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320343000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	322530000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	300000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	141000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	USD
CY2017Q4	us-gaap	Assets Assets	6706000	USD
CY2018Q1	us-gaap	Assets Assets	6020000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6592000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	5918000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3762000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6331000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5678000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1675000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-653000	USD
CY2017Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	11500000	USD
CY2018Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1504000	USD
CY2018Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.80
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5810000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15217231	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16341080	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15217231	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16341080	shares
CY2018Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2271000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.44
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2017Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	12000	USD
CY2018Q1	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	12000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	46000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	20000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	694000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12317000	USD
CY2017Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	1.48
CY2018Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12709000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.04
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1008000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-222000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1441000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2135000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3404000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.14
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11477000	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-202000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	286000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	479000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	144000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	124000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-446000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-16000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-156000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-95000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	92000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2335000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	1732000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6706000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6020000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1583000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1690000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	9996000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-7129000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1275000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1192000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10600000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1928000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1900000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	8073000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-2271000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1551000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	1853000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	2352000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1853000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2352000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	0	USD
CY2018Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	10000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	695000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	369000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1064000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.37
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.40
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.11
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1275000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4371000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	240000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66000	USD
CY2017Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2018Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	141000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	412000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	217000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315987000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-318258000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	284000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	300000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0229
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0227
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1041000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	233000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7084000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5810000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	700000	shares
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	4288000	USD
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7737000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15971000	shares

Files In Submission

Name	View Source	Status
0001017491-18-000059-index-headers.html	Edgar Link	pending
0001017491-18-000059-index.html	Edgar Link	pending
0001017491-18-000059.txt	Edgar Link	pending
0001017491-18-000059-xbrl.zip	Edgar Link	pending
apri-20180331.xml	Edgar Link	completed
apri-20180331.xsd	Edgar Link	pending
apri-20180331_cal.xml	Edgar Link	unprocessable
apri-20180331_def.xml	Edgar Link	unprocessable
apri-20180331_lab.xml	Edgar Link	unprocessable
apri-20180331_pre.xml	Edgar Link	unprocessable
apri3311810q.htm	Edgar Link	pending
apri33118ex311.htm	Edgar Link	pending
apri33118ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2018 Q2 Form 10-Q Financial Statement

#000101749118000059 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2018 Q2 Form 10-Q Financial Statement

#000101749118000059 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel